Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

NCT03020004 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Danoprevir
DRUG: Ritonavir
DRUG: peginterferon alfa-2a
DRUG: Ribavirin (RBV)

Sponsor

Ascletis Pharmaceuticals Co., Ltd.